REDUCTION IN MICROALBUMINURIA IN DIABETICS BY EICOSAPENTAENOIC ACID ETHYL-ESTER
REDUCTION IN MICROALBUMINURIA IN DIABETICS BY EICOSAPENTAENOIC ACID ETHYL-ESTER
复制标题
作者：
HAMAZAKI, T;TAKAZAKURA, E;YANO, S
16例糖尿病患者（5例胰岛素依赖型，11例非胰岛素依赖型）口服二十碳五烯酸（EPA）乙酯1.8g/d，疗程6个月。总血浆脂肪酸中的EPA从4.0 . ±. 2.4摩尔%（平均值±. SD）至7.5 . ±-。3.1 mol%（p < 0.001）。用点尿测量的白蛋白排泄量从65 mg/g肌酐显著降低至36 mg/g肌酐（几何平均值，p < 0.001）。研究期间，空腹血糖水平、糖化血红蛋白、体重和血压没有显著变化。血清肌酐、尿素氮、总胆固醇和甘油三酯水平也无显著变化。虽然在患者中没有观察到明显的出血，但红细胞压积从42.6 . ±. 2.8%至41.0 .+-. 3.9%（p < 0.02）。其他10名类似的糖尿病患者（4名胰岛素依赖型和6名非胰岛素依赖型糖尿病患者）作为参照组，不同时，6个月既没有EPA乙酯，也没有安慰剂。6个月内上述指标无明显变化。EPA的管理可能会延迟出现明显的糖尿病肾病。
Eicosapentaenoic acid (EPA) ethyl ester (1.8 g/d) was administered to 16 diabetic patients (5 insulin-dependent and 11 noninsulin-dependent diabetics) for 6 mon. EPA in total plasma fatty acids increased from 4.0 .+-. 2.4 mol% (mean .+-. SD) to 7.5 .+-. 3.1 mol% (p < 0.001). Albumin excretion, measured with spot urine, was significantly reduced from 65 to 36 mg/g creatinine (geometric means, p < 0.001). Fasting blood sugar levels, glycohemoglobin, body weight and blood pressure did not change significantly during the study. There were also no significant changes in serum levels of creatinine, urea nitrogen, total cholesterol and triglycerides. Although no overt hemorrhage was observed in the patients, hematocrit was reduced from 42.6 .+-. 2.8% to 41.0 .+-. 3.9% (p < 0.02). Ten other similar diabetic patients (4 insulin-dependent and 6 non-insulin-dependent diabetics) were followed as a reference group, not concomitantly, for 6 mon with neither EPA ethyl ester nor placebo. The parameters mentioned above were not changed significantly in this group during 6 mon. EPA administration might retard the appearance of overt diabetic nephropathy.